Hims & Hers Shares Rise Nearly 6% as Peptide Plan Reaches White House Review
Hims & Hers Health shares rose nearly 6% Thursday, ending a three-day losing streak. A Trump administration plan to ease restrictions on peptide compounding reached White House review; the stock was down 5% for the week.
Hims & Hers Health (HIMS) shares climbed nearly 6% on Thursday, ending a three-day decline as a Trump administration proposal to loosen restrictions on peptide compounding reached White House review. The stock was down 5% for the week, putting it on track for its steepest weekly loss in nearly two months.